Abstract: Antibodies made to a flanking region GPR(31-8) in human gastrin-releasing peptide (GRP) precursor. Since the antibodies have high affinity to GRP precursor, and the GPR precursor is highly stable in the blood, then lung cancer, especially small cell lung cancer can be diagnosed with high reliability by detecting or measuring GRP precursor in the blood of a patient using the present antibodies.
Type:
Grant
Filed:
February 11, 1993
Date of Patent:
August 27, 1996
Assignees:
Tonen Corporation, Terumo Corporation, Ken Yamguchi